Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods

Ivo Rausch 1 · Andreas Zitterl 2 · Neydher Berroterán-Infante 1 · Lucas Rischka 3 · Daniela Prayer 4 · Matthias Fenchel 5 · Reza A. Sareshgi 2,6 · Alexander R. Haug 2 · Marcus Hacker 2 · Thomas Beyer 1 · Tatjana Traub-Weidinger 2

Received: 10 July 2018 / Revised: 14 November 2018 / Accepted: 30 November 2018 / Published online: 11 January 2019

Abstract

Aim To assess if tumour grading based on dynamic [18F]FET positron emission tomography/magnetic resonance imaging (PET/MRI) studies is affected by different MRI-based attenuation correction (AC) methods.

Methods Twenty-four patients with suspected brain tumours underwent dynamic [18F]FET-PET/MRI examinations and subsequent low-dose computed tomography (CT) scans of the head. The dynamic PET data was reconstructed using the following AC methods: standard Dixon-based AC and ultra-short echo time MRI-based AC (MR-AC) and a model-based AC approach. All data were reconstructed also using CT-based AC (reference). For all lesions and reconstructions, time-activity curves (TACs) and time to peak (TTP) were extracted using different region-of-interest (ROI) and volume-of-interest (VOI) definitions. According to the most common evaluation approaches, TACs were categorised into two or three distinct curve patterns. Changes in TTP and TAC patterns compared to PET using CT-based AC were reported.

Results In the majority of cases, TAC patterns did not change. However, TAC pattern changes as well as changes in TTP were observed in up to 8% and 17% of the cases when using different MR-AC methods and ROI/VOI definitions, respectively. However, these changes in TTP and TAC pattern were attributed to different delineations of the ROIs/VOIs in PET corrected with different AC methods.

Conclusion PET/MRI using different MR-AC methods can be used for the assessment of TAC patterns in dynamic [18F]FET studies, as long as a meaningful delineation of the area of interest within the tumour is ensured.

Key Points
• PET/MRI using different MR-AC methods can be used for dynamic [18F]FET studies.
• A meaningful segmentation of the area of interest needs to be ensured, mandating a visual validation of the delineation by an experienced reader.

Keywords Brain neoplasms · Positron emission tomography · Magnet resonance imaging · Radionuclide imaging

Abbreviations
AC Attenuation correction
CT-AC CT-based attenuation correction
MR-AC MRI-based attenuation correction
ROI Region of interest
SUV Standardised uptake value
TAC Time-activity curve
TBR Tissue-to-background ratio

© The Author(s) 2019

European Radiology (2019) 29:4276–4285
https://doi.org/10.1007/s00330-018-5942-9
Introduction

Positron emission tomography (PET) is a well-established tool for tumour imaging in neuro-oncology. PET imaging using amino acid tracers has been demonstrated to be of particular value for the diagnosis, prognosis and therapy response assessment of glioma patients [1–3]. Moreover, amino acid PET is used for target definition in radiation therapy and for guided surgical biopsy [4, 5]. Among the available amino acid tracers, [18F]2-fluoroethyl-L-tyrosine ([18F]FET) is one of the most frequently used. Several studies have shown the value of [18F]FET for the assessment of gliomas [1, 6–9]. Moreover, its clinical adoption has been recently recommended by the Response Assessment in Neuro-Oncology Working Group together with the European Association for Neuro-Oncology [2]. Particularly, the observed [18F]FET uptake behaviour within a brain tumour lesion over the time evaluated by different PET techniques enables a better understanding for brain tumour grading with the possibility to detect anaplastic foci and treatment response [10–13].

These evaluation techniques are based on a classification of the tracer uptake over time into two [14] or three [15] curve patterns and have shown to increase the diagnostic accuracy in relatively large patient cohorts in stand-alone PET and PET/CT examinations.

With the introduction of fully integrated PET and magnetic resonance imaging (PET/MRI), a new modality has become available, which has the potential to improve the diagnostic accuracy compared to PET or PET/CT imaging. The MRI component not only provides a high-resolution and high-contrast anatomical reference for the tracer distribution but also helps probe cellular and molecular pathways through advanced MRI techniques, such as diffusion-weighted imaging, perfusion imaging and spectroscopy [16, 17]. These advanced MRI techniques enable a more detailed soft tissue analysis and showed promising results for an improvement in discriminating malignant from benign lesions and glioma grading [18, 19]. However, only few studies have been published regarding the impact of combined PET/MRI in the clinical management of glioma patients [19, 20] and PET/MRI has primarily been suggested to be beneficial especially in paediatric patients [21]. In this patient group, the reduced radiation burden arising from the CT component in PET/CT examinations is particularly desirable. Further, general anaesthesia is often required for paediatric patients for MRI as well as PET. Performing both examinations simultaneously in one PET/MRI session has the advantage of reduced risks related to anaesthesia in this group of patients.

Nevertheless, clinical PET/MRI is still challenged by technical issues related to attenuation correction (AC) [22]. Reasons are that MRI information is not related to the attenuation properties of the investigated tissue [23]. Further, the visualisation of bone is challenging in MRI, and thus, standard MRI-based AC (MR-AC) methods do not account for bone, which has been shown to yield a regionally variable bias in the reconstructed tracer distribution [24]. Several MR-AC methods have been developed to overcome this issue [25]. However, for clinical routine, just three methods are available in current PET/MRI systems. These include the standard Dixon-based MR-AC method, an ultra-short echo time (UTE)-based method and a model-based approach [26–29]. The quantitative accuracy of these MR-AC methods has been assessed for static PET examinations and standardised uptake values (SUVs) [22, 24, 25, 28, 29]. However, none of these studies assessed the influence of the available MR-AC methods on the dynamic evaluation of [18F]FET examinations by means of a categorisation of the uptake pattern into different pattern classes. On first glance, one could assume that a bias in quantification only results in a scaling of the tracer uptake patterns but does not change the shape, and therefore, the categorisation of the patterns itself. However, as the above-mentioned studies revealed spatially variant biases in quantitative readings and the uptake patterns are extracted from regions selected based on the tracer distribution, a straightforward translation of the established techniques to PET/MRI is probably not possible.

Therefore, the aim of our study was to evaluate if the established classification of uptake curves of dynamic [18F]FET PET imaging of glioma patients is applicable to PET/MRI data using different MR-based attenuation correction techniques.

Materials and methods

Subjects and study protocol

This study included 24 patients (20 female, mean age ± SD = 49 ± 14 years) referred for a [18F]FET-PET examination due to findings in earlier performed MRI examinations. These findings included suspected primary (n = 5) and recurrent (n = 11) gliomas as well as suspected metastasis (n = 8). For further details, see Table 1. All patients underwent a PET/MRI examination of the brain (Biograph mMR, Siemens Healthineers) starting with a bolus injection of about 200 MBq [18F]FET. PET emission data were acquired in listmode for 40 min. The protocol included the acquisition of the following MR sequences: standard Dixon, standard UTE and an anatomical T1-weighted MRI of the brain (MP-RAGE, TE = 4.2 ms, TR = 2000 ms, voxel size = 1 mm × 1 mm × 1 mm). Following the PET/MR...
examination, an additional low-dose CT of the head was acquired on a whole-body PET/CT system (Biograph TPTV, Siemens Healthcare GmbH) for the purpose of CT-based attenuation correction (CT-AC). This study was approved by the Ethics Committee of the Medical University of Vienna (EK-No. 1828/2016). All patients did give their written informed consent before the examination.

**Data processing**

For each acquisition, the 40-min dynamic PET data were reconstructed into eight frames (2 × 2 min, 4 × 4 min, 2 × 10 min) using four different attenuation corrections: standard Dixon-based MR-AC (Dixon-AC) [26], standard UTE-based MR-AC (UTE-AC) [28], model-based MR-AC and CT-AC [29, 30] (Fig. 1). In short, the Dixon-AC is based on the Dixon technique [31] and results in a four-class AC map with uniform linear attenuation coefficients for soft tissue, fat, air and, if applicable, lung [27]. The UTE-AC is based on an ultra-short echo time sequence enabling the generation of an AC map categorising the head into three tissue classes (soft tissue, bone and air) [28]. Finally, the model-based AC incorporates spatially variant attenuation coefficients of the major bone structures into the Dixon-AC [29, 30]. It employs a prototype version of the five compartment AC method available for the mMR PET/MRI system in software version E11.

We use the images following CT-AC as a reference standard. For the CT-AC, the low-dose CT acquired with the PET/CT was co-registered rigidly to the anatomical T1-weighted MRI images after removal of the patient bed from the PET/CT. Then, the CT image volume was resampled to the spatial resolution of the Dixon-AC map and the Hounsfield units were converted into linear attenuation values for 511 keV photons using the same segmentation/bi-linear scaling approach as used in the PET/CT system [32].

All image reconstructions were performed on an external workstation (e7tools, Siemens Healthcare GmbH) using an ordinary Poisson ordered-subset expectation maximisation (OP-OSEM) algorithm with the following image reconstruction settings: 3 iterations, 21 subsets, matrix size = 172 × 172,

| Patient | Age | Sex | Indication for 18F[FDG] PET/MR | Therapy before PET/MR | Diagnosis based on histology | Localisation |
|---------|-----|-----|-------------------------------|------------------------|-----------------------------|--------------|
| 1       | 22  | F   | Primary                       | None                   | Anaplastic astrocytoma II–III* | Frontotemporal left |
| 2       | 43  | M   | Recurrent                     | OP, CH, RT, GKN       | Anaplastic astrocytoma III   | Temporal left  |
| 3       | 37  | F   | None                          |                        | Not established (suspected low grad glioma) | Operculum right |
| 4       | 52  | F   | Recurrent                     | RT                     | Diffuse astrocytoma II       | Pons          |
| 5       | 51  | F   | Recurrent                     | CH, RT                 | Oligodendroglioma II         | Temporal left  |
| 6       | 27  | F   | Primary                       | None                   | Not established (suspected low grad glioma) | Thalamus left  |
| 7       | 53  | F   | Metastasis                    | CH, RT, GKN           | Breast carcinoma*            | Frontal right  |
| 8       | 38  | M   | Primary                       | None                   | Diffuse astrocytoma II*      | Frontal left   |
| 9       | 44  | F   | Recurrent                     | OP                     | Oligodendroglioma II         | Frontal left   |
| 10      | 69  | F   | Metastasis                    | CH, RT, GKN           | Breast carcinoma             | Cerebellar right |
| 11      | 34  | F   | Recurrent                     | CH, RT                 | Diffuse fibrillar astrocytoma II–III | Basal ganglia right |
| 12      | 55  | F   | Metastasis                    | OP, RT, CH, GKN       | Cervix carcinoma*            | Frontal left   |
| 13      | 37  | F   | Recurrent                     | OP, RT, CH            | Glioblastoma                 | Frontal left   |
| 14      | 26  | F   | Recurrent                     | OP                     | Diffuse astrocytoma II       | Parietal right |
| 15      | 63  | F   | Primary                       | None                   | Oligodendroglioma II*        | Temporal left  |
| 16      | 45  | F   | Recurrent                     | OP                     | Diffuse astrocytoma II–III   | Parietal right |
| 17      | 59  | F   | Recurrent                     | OP, RT, CH            | Anaplastic oligodendroglioma III | Frontal left   |
| 18      | 75  | M   | Metastasis                    | CH, ST, GKN           | Lung carcinoma               | Frontal left   |
| 19      | 51  | F   | Metastasis                    | OP, CH, GKN           | Lung carcinoma               | Temporal, occipital right |
| 20      | 53  | F   | Recurrent                     | OP, RT                | Anaplastic oligoastrocytoma III | Frontal, temporal right |
| 21      | 46  | F   | Recurrent                     | OP, CH                | Anaplastic oligoastrocytoma II–III | Frontal right |
| 22      | 67  | F   | Metastasis                    | CH, GKN               | Breast carcinoma             | Parietal right |
| 23      | 66  | F   | Metastasis                    | CH, GKN               | Breast carcinoma             | Frontal right  |
| 24      | 64  | F   | Metastasis                    | CH, GKN               | Melanoma                     | Cerebellar right |

*Female, M male, OP surgery, RT radiation therapy, CH chemotherapy, GKN gamma-knife therapy

Histology was established after PET/MR examination
zoom factor = 2 and post-reconstruction filter = 3 mm FWHM Gaussian kernel.

**Data evaluation**

The evaluation of the dynamic [18F]FET studies was based on the most common evaluation approaches as described by Jansen et al [10, 11] and Pöpperl et al [14, 33] and Galldiks et al [15, 34]. In general, all methods followed the same concept. First, a summed PET image is generated from the last 20 min of the acquisition (21–40 min post tracer injection). Then, tumours are delineated using region of interest (ROI) or volume of interest (VOI). In this work, ROI refers to a connected area in one single image slice. VOI refers to a connected volume, which can include connected voxels from multiple slices. ROIs and VOIs are copied to all time frames of the dynamic PET data, and time-activity curves (TACs) are extracted from this data. TACs are composed of the average SUV of all voxels in a ROI or VOI within a reconstructed frame and the time elapsed from the start of the acquisition to the end of the respective frame. These TACs are then categorised by their shapes into different TAC patterns, which are linked to differences in expected overall survival time or represent different tumour grades [14, 15]. The differences between the methods used by different groups are found in the ROI or VOI definition and in the pattern categories.

In this study, we replicated the most common evaluation techniques published by Jansen et al [10, 11] and Pöpperl et al [14] as well as Galldiks et al [15, 34]. In accordance with their published methodology, the following ROI and VOI definitions and pattern categories combinations were used:

- **ROI90**: ROI in the axial slice with the highest uptake in the tumour generated by a threshold-based region growing including all (surrounding and connected) voxels whose SUVs were equal or greater than 90% of the of the maximum SUV within the tumour
- **VOI90**: Similar to ROI90, but in three dimensions

Similar to Jansen et al [10] and Pöpperl et al [14], TACs extracted using ROI90 and VOI90 were categorised into the following [18F]FET uptake patterns:

(I) Increasing, with [18F]FET uptake constantly increasing, and

(II) Decreasing, with TAC reaching a maximum within 20 min, followed by a decrease

- **ROI_{TBR}**: ROI in the axial slice with the highest uptake in the tumour generated by a threshold-based region growing including all (surrounding and connected) voxels with SUV equal to or higher than 1.6 times the background tracer concentration. The background uptake is determined as the average tracer concentration in a spherical, 2-cm-diameter VOI placed contralateral on an unaffected brain region (enclosing grey and white matter)
- **VOI_{TBR}**: Similar to ROI_{TBR}, but in three dimensions
- **VOI_{Fix}**: Spherical VOI of ~ 2 mL volume (1.56 cm diameter) centred around the maximum tracer uptake in the tumour [15]

Similar to Galldiks et al [15, 34], TACs extracted using ROI_{TBR}, VOI_{TBR} and VOI_{Fix} were categorised into the following [18F]FET uptake patterns:

(I) Increasing, with [18F]FET uptake constantly increasing,

(II) Plateau, with TAC reaching a maximum between 20 and 40 min followed by a plateau or slight descent, and

(III) Decreasing, with TAC showing an early peak within 20 min followed by a continuous descent

Lesion definition and TAC extraction were performed using the Hermes Hybrid Viewer software (version 2.6, Hermes Medical). TACs extracted from threshold-based VOIs (VOI_{90}, VOI_{TBR}), but with the threshold being too low for a meaningful segmentation (i.e. segmentation included large fractions of the neck and the viscerocranium), were
excluded from further analysis. For all ROI and VOI definitions, changes in the corresponding TAC categorisation were reported as a function of the MR-AC method.

In addition to the assessment of changes in the TAC categorisation, changes in time to peak (TTP), which is the elapsed time between tracer injection and maximum tracer concentration in the target region within the 40 min post injection, were evaluated for all ROI and VOI definitions and MR-AC methods. Furthermore, differences in the tissue-to-background ratio (TBR) in the last 10-min frame (31–40 min post tracer injection) and threshold-defined volumes in PET images reconstructed with the different MR-AC methods were reported.

To evaluate the sole contribution of the MR-AC on the tracer uptake pattern, TACs were additionally extracted from VOIs placed at exactly the same location for all MR-AC methods. Therefore, an experienced nuclear medicine physician (>10 years of experience in neuro-oncological imaging) placed spherical VOIs of 1 cm diameter within the 18F-FET avid lesion on the CT-AC reconstructions, thereby avoiding the inclusion of obviously non-malignant structures (e.g. major blood vessels). These VOIs were then copied to the MR-AC PET images, and TACs were extracted. These TACs were categorised according to all above-mentioned methods, and MR-AC-dependent changes in TAC categorisation and TTP were assessed.

Results

TACs were extracted from ROI90, ROI TBR and VOI Sphere for all 24 patients. Using VOI90 and VOI TBR, TACs were extracted for 23 and 17 patients, respectively. For the remaining patients, VOI90 and VOI TBR segmentations included large parts of the head in at least one of the reconstructions and, therefore, were excluded.

No change in TAC pattern was observed for TACs extracted from VOI90 and VOI Fix. For ROI90, ROI TBR and VOI TBR changes in TAC pattern categorisations were observed in up to 4%, 8% and 6% of the examinations when using different MR-AC methods, respectively. Table 2 summarises the percentage of changes in TAC categories depending on the choice of the MR-AC method in relation to the reference standard (CT-AC). In cases where TAC categorisation did change, differences in the delineated ROI/VOI by means of their volume and location could be observed (Figs. 2 and 3). TTP changes were found for all ROI/VOI definitions in a varying percentage of cases depending on the used MR-AC method (Table 3).

TBRs were similar for all AC methods and ROI/VOI definitions. Average deviations of TBRs compared to TBRs after CT-AC PET were between 0 and −3%, depending on the ROI/VOI definition and MR-AC method. Figure 4 depicts the changes in TBRs compared to CT-AC PET. The median absolute delineated volumes in the CT-AC PET where 0.1 mL, 0.6 mL, 0.3 mL and 4 mL for ROI90, ROI TBR, VOI90 and VOI TBR, respectively. Average changes of volumes of the ROIs/VOIs in relation to CT-AC PET were between +8% and −17% when using different MR-AC methods and ROI/VOI definitions with maximum relative changes of ROI/VOI volumes of up to −63% (ROI TBR, model-based AC) and +138% (ROI90, model-based AC) (Fig. 5). However, changes in absolute delineated volumes >1 mL only occurred for VOI TBR-based delineations in five cases.

The evaluation of the sole MR-AC-based contribution on the uptake pattern categorisation revealed that for the exactly similar located VOI, no changes in pattern categorisation and TTP were present.

Discussion

This study evaluated if TAC pattern categorisations of dynamic [18F]FET PET seems to be feasible, regardless of the choice of the MR-AC method.

In general, local biased quantitative readings (e.g. SUVs) are known to occur in PET after MR-AC when compared to reference CT-AC [22, 24, 25]. Such bias results from known limitations of MR-AC, such as incorrect assumptions of local tissue attenuation [25], and thus, to locally biased readings of the attenuation-corrected emission data. However, in dynamic emission studies, all time frames are corrected using the same AC map. Thus, a relative quantitative bias in a certain location should be stable for all reconstructed time frames as long as movement artefacts can be neglected. Such a systematic error will lead to a scaling of the quantitative readings but should not influence the shape of a TAC for a given ROI or VOI. Furthermore, any quantitative bias in brain PET/MRI is approximately symmetrical across both brain hemispheres [22, 29]. Therefore, TBR should be similar between different AC methods when sampling the background tracer uptake contralateral to the evaluated ROI or VOI. These assumptions are also confirmed by our results, where similar TBR values are found for all AC methods (Fig. 4) and no changes in categorisation and TTP were present for the TACs extracted from the VOIs placed at exactly the same location for all AC methods.

However, in this study, TAC pattern changes as well as shifts in time of the TTP, when using established methodology with different MR-AC methods, were observed in up to 8% and 17% of the cases, respectively. These changes are attributed to differences in the segmented ROI or VOI. Threshold-
based region growing segmentations depend on the set threshold value and on the local tracer distribution. A locally varying bias of PET activity, as observed in PET images after MR-AC [24], may affect the representation of a local tracer distribution and, thus, contributes to differences in the segmented volume (Fig. 2). These volumes also represent diverging investigated areas and, thus, distinct tissues with individual uptake behaviours. Furthermore, another segmented area may also represent a tumour area with an altered uptake pattern, given the possibility of a heterogeneous tumoural lesion.

In addition to altered segmentations within a lesion, obviously wrong segmentations were found in the evaluated datasets. Such errors in segmentations were most prominent when the tumour was located near other anatomical structures with physiological [18F]FET accumulation (e.g. blood vessels or scalp). In such cases, the threshold-based segmentation methods could not always distinguish increased [18F]FET uptake of a tumour from the increased uptake of non-tumoural tissue reliably. Figure 3 shows an example where a blood vessel was included in the VOI TBR following model-based MR-AC. As a result, the TAC was a mixture of the blood TAC (input function) and the TAC of the lesion. In this case, an exclusion of the blood vessel would have resulted in similar TAC patterns for all AC methods. Such issues are an inherent property of semiautomatic thresholding algorithms. Therefore, an incorrect tumour segmentation cannot be

| AC method          | 2 TAC pattern categories | 3 TAC pattern categories |
|--------------------|--------------------------|--------------------------|
|                    | ROI<sub>90</sub> (%) | VOI<sub>90</sub> (%) | ROI<sub>TBR</sub> (%) | VOI<sub>TBR</sub> (%) | VOI<sub>Fix</sub> (%) |
| Dixon              | 0                        | 0                        | 8                        | 6                        | 0                        |
| UTE                | 4                        | 0                        | 4                        | 0                        | 0                        |
| Model-based        | 0                        | 0                        | 8                        | 6                        | 0                        |

**Fig. 2** a ROI<sub>90</sub> and ROI<sub>TBR</sub> delineated on the summed (20–40 min) PET images following three MR-AC and the CT-AC methods. In the CT-AC and UTE-AC PET, the ROI<sub>TBR</sub> included physiological [18F]FET uptake in the scalp. Further, in the UTE-AC PET, the ROI<sub>TBR</sub> segmentation resulted in an extended ROI when compared to ROI<sub>TBR</sub> in the Dixon-AC and model-based AC PET. b TAC extracted from ROI<sub>90</sub> and ROI<sub>TBR</sub> in PET images corrected using the different AC methods.
attributed to a specific AC method and, thus, can also occur after CT-AC.

In general, segmentations with high thresholds (e.g. a threshold of 90% of the maximum uptake) appear to be more stable by means of changes of the segmented region. However, the differences in bias distribution from different MR-AC methods can lead to a change in the location of the maximum uptake in a lesion. This will lead to a change of the starting point of the region growing and, again, will result in a different delineated area. The differences found for TTP extracted from the VOI\textsubscript{Fix} are also partly attributed to changes of the maximum pixel location. Moreover, TTP changes could be caused by small adjustments by the experienced reader when manually placing the VOI\textsubscript{Fix}, thus reflecting intra- and inter-reader variabilities. Nevertheless, for the categorisation of TACs, VOI\textsubscript{Fix} showed the most stable behaviour (Table 2) and the exclusion of obviously non-tumoural tissue could be ensured by the experienced reader.

A change in the appearance of the local tracer distribution and the location of the maximum uptake in a lesion could potentially also influence [18F]FET PET-based targeted biopsy [1, 5, 13] or radiotherapy planning [35]. Especially, in radiation therapy planning, threshold-based delineation approaches are often used [36, 37]. Here, similar changes of delineated volumes for different MR-AC concepts as found in this study can be expected. These variabilities of volumes might be of minor impact for high threshold values (e.g. VOI\textsubscript{90}), due to the small absolute volume changes (< 1 mL). However, for low threshold segmentations (e.g. VOI\textsubscript{TBR}), such volume changes might be significant.

In this study, the used methods for tumour segmentations were replications of published methodologies for which the diagnostic value of dynamic [18F]FET PET was proved in large patient cohorts for stand-alone PET examinations [10, 14, 15, 34]. These methods are based on region growing algorithms applied to PET images (except the VOI\textsubscript{Fix}) and do not take into account a potential involvement of structures with physiological uptake. Therefore, the definition of the region of interest should not be purely based on PET images. Especially in the case of PET/MRI, where co-localised anatomical information is available, this information should be additionally utilised for the delineation of the targeted structures (Fig. 3).

However, even with purely PET-based delineation methods, only a small proportion of the evaluated TAC patterns were categorised differently when using different MR-

**Table 3**: Number of patients in relation to the total number of evaluated patients where TTP derived from ROI and VOI analysis of PET data changed following MR-AC as compared to CT-AC

| AC method | ROI\textsubscript{90} | VOI\textsubscript{90} | ROI\textsubscript{TBR} | VOI\textsubscript{TBR} | VOI\textsubscript{Fix} |
|-----------|----------------|----------------|----------------|----------------|----------------|
| Dixon     | 2/24 (1, 2)   | 0/23           | 3/24 (1, 1, 3)  | 1/17 (1)       | 1/24 (1)       |
| UTE       | 2/24 (1, 3)   | 4/23 (1, 1, 1) | 3/24 (1, 1, 1)  | 1/17 (2)       | 2/14 (1, 1)    |
| Model-based| 2/24 (1, 1)  | 1/23 (1)       | 4/24 (1, 2, 3, 6)| 2/17 (2, 6)    | 2/24 (1, 1)    |

The numbers in brackets are the $\Delta$TTP in units of time frames for the cases where TTP changed (e.g. (1,3) means TTP shifted one time frame in one case and three time frames in another).
AC methods. TACs extracted from fixed VOIs and threshold-based segmentations with conservatively high thresholds only defining the most metabolic active areas showed the most stable behaviour. Segmentations based on relatively low thresholds (e.g. 1.6 times the background) aiming on a segmentation of the total tumour volume were more likely to

Fig. 4 Relative difference of TBRs using the three MR-based AC methods in comparison to the TBRs extracted from PET after CT-AC

Fig. 5 Relative difference of the PET-based ROI and VOI for the three MR-AC methods in comparison to the ROI and VOI following CT-AC
result in different TAC patterns. However, none of the investigated delineation methods has shown a 100% reproducible segmentation of the investigated area in all cases.

**Limitations**

The study protocol did not include motion correction of the dynamic PET data. Solely foam wedges were used to limit subject motion. Therefore, motion artefacts cannot be ruled out. However, no influence of motion artefacts on the results of the pattern comparison is expected as the same raw data was used in all reconstructions, and thus, an artefact will influence all reconstructions similarly. Nevertheless, motion compensation is highly recommended for dynamic studies as motion artefacts could influence the pattern categorisation.

In this study, a high prevalence of lesions with relatively low tracer uptake was present. We assume that the rate of failing segmentations using VOI\textsubscript{90} and VOI\textsubscript{TBR} is lower in patient cohorts with higher tracer uptake in the lesions.

**Conclusion**

Established uptake curve evaluation methods used for glioma characterisation in dynamic \([18F]\)FET PET can be applied to PET/MRI using all investigated MR-AC techniques. However, quantitative readings by means of SUV may be biased depending on the used MR-AC. Moreover, a meaningful segmentation of the area of interest needs to be ensured with all AC methods. This mandates a visual validation of the ROI or VOI by an experienced reader, preferably also using the additional anatomical information as provided by the MRI component of the PET/MRI system.

**Acknowledgements**Open access funding provided by Medical University of Vienna. We want to thank the technologists team operating the PET/MRI and performing the dynamic \([18F]\)FET examinations at the General Hospital of Vienna. Lucas Rischka is the recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna.

**Funding**This study was supported by a research grant as part of a Master research agreement between the Medical University of Vienna and the Siemens Healthcare GmbH. Lucas Rischka is the recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna.

**Compliance with ethical standards**

**Guarantor**The scientific guarantor of this publication is Alexander Haug.

**Conflict of interest**Matthias Fenchel is an employee of Siemens Healthcare GmbH.

**Statistics and biometry**No complex statistical methods were necessary for this paper.

**Informed consent**Written informed consent was obtained from all subjects (patients) in this study.

**Ethical approval**All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the Medical University of Vienna (EK-No. 1828/2016).

**Methodology**

- retrospective
- diagnostic or prognostic study
- performed at one institution

**Open Access**This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**Publisher's Note**Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Hutterer M, Nowosielski M, Putzer D et al (2013) \([18F]\)-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 15:341–351
2. Albert NL, Weller M, Suchorska B et al (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of \(18F\) PET imaging in gliomas. Neuro Oncol 18:1199–1208
3. Galldiks N, Langen KJ (2017) Amino acid PET in neuro-oncology: applications in the clinic. Expert Rev Anticancer Ther 17:395–397
4. Badakhshi H, Graf R, Prasad V, Budach V (2014) The impact of \(18F\)-FET PET-CT on target definition in image-guided stereotactic radiotherapy in patients with skull base lesions. Cancer Imaging 14:25
5. Misch M, Guggemos A, Driever PH et al (2015) \(18F\)-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. Childs Nerv Syst 31:261–267
6. Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of \(18F\)-fluoro-ethyl-tyrosine \((18F\)–FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 53:207–214
7. Galldiks N, Langen KJ, Holy R et al (2012) Assessment of treatment response in patients with glioblastoma using O-(\(-18F\)-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 53:1048–1057
8. Roeckle U, Wyss MT, Nowosielski M et al (2016) Amino acid positron emission tomography to monitor chemotherapy response
and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro Oncol 18:744–751
9. Jansen NL, Suchorska B, Schwarz SB et al (2013) [18F]fluoroethyltyrosine-posi-тоном emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging 12:137–147
10. Jansen NL, Graute V, Armbuster L et al (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029
11. Jansen NL, Schwartz C, Graute V et al (2012) Prediction of oligo- dendrogial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol 14:1473–1480
12. Galldiks N, Stoffels G, Filss C et al (2012) Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 53:1367–1374
13. Kunz M, Thon N, Eigenbrod S et al (2011) Hot spots in dynamic [(18)F]FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 13:307–316
14. Pöpperl G, Kreth FW, Mehrkens JH et al (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942
15. Galldiks N, Stoffels G, Filss C et al (2015) The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol 17:1293–1300
16. Lee K, Ott GA, Lai A et al (2017) Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. J Neurooncol 134:177–188
17. Branzoli F, Di Stefano AL, Capelle L et al (2018) Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Neuro Oncol 20:907–916
18. Ellingson BM, Bendszus M, Sorensen AG, Pope WB (2014) Emerging techniques and technologies in brain tumor imaging. Neuro Oncol 16(Suppl 7):vii12–vii23
19. Jena A, Taneja S, Gambhir A et al (2016) Glioma recurrence versus radiation necrosis. Clin Nucl Med 41:e228–e236
20. Henriksen OM, Larsen VA, Muhic A et al (2016) Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging 43:103–112
21. Mamer L, Henriksen OM, Lundemann M, Larsen VA, Law I (2017) Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging 5:135–149
22. Rausch I, Rischka L, Ladeoged CN et al (2017) PET/MRI for oncologic brain imaging: a comparison of standard MR-based attenuation corrections with a model-based approach for the Siemens mMR PET/MR system. J Nucl Med 58:1519–1525
23. Wagenknecht G, Kaiser HJ, Mottaghy FM, Herzog H (2013) MRI for attenuation correction in PET: methods and challenges. MAGMA 26:99–113
24. Andersen FL, Ladeoged CN, Beyer T et al (2014) Combined PET/ MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage 84:206–216
25. Ladeoged CN, Law I, Anazodo U et al (2017) A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. Neuroimage 147:346–359
26. Martinez-Möller A, Souvatzaglou M, Delso G et al (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 50:520–526
27. Rausch I, Rust P, DiFranco MD et al (2016) Reproducibility of MRI Dixon-based attenuation correction in combined PET/MR with applications for lean body mass estimation. J Nucl Med 57:1096–1101
28. Aasheim LB, Karlberg A, Goa PE et al (2015) PET/MR brain imaging: evaluation of clinical UTE-based attenuation correction. Eur J Nucl Med Mol Imaging 42:1439–1446
29. Koesters T, Friedman KP, Fenchel M et al (2016) Dixon sequence with superimposed model-based bone compartment provides highly accurate PET/MR attenuation correction of the brain. J Nucl Med 57:918–924
30. Paulus DH, Quick HH, Geppert C et al (2015) Whole-body PET/ MR imaging: quantitative evaluation of a novel model-based MR attenuation correction method including bone. J Nucl Med 56:1061–1066
31. Ma J (2008) Dixon techniques for water and fat imaging. J Magn Reson Imaging 28:543–558
32. Carney JPJ, Townsend DW, Rappoport V, Bendriem B (2006) Method for transforming CT images for attenuation correction in PET/CT imaging. Med Phys 33:976–983
33. Pöpperl G, Kreth FW, Herms J et al (2006) Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393–403
34. Galldiks N, Stoffels G, Ruge MI et al (2013) Role of O-(2-18F-Fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 54:2046–2054
35. Debas C, Wullenberger M, Floca R et al (2018) Impact of 18F-FET PET on target volume definition and tumor progression of recurrent high grade glioma treated with carbon-ion radiotherapy. Sci Rep 8:7201
36. Prioth MD, Pinkawa M, Holy R et al (2012) Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Strahlenther Onkol 188:334–339
37. Rieken S, Habermehl D, Giesel FL et al (2013) Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformational radiotherapy. Radiother Oncol 109:487–492